Skip to main content

Table 1 Patient characteristics

From: Characteristics and outcomes analysis of ovarian Sertoli–Leydig cell tumors (SLCTs): analysis of 15 patients

No Age Clinical manifestation Parturition Laboratory Ultrasound Histopathology Treatment Relapse Follow-up
Side D (cm) Diagnosis Stage Surgery Chemotherapy Period Status
1 26 Amenorrhea NO Testosterone↑
AFP ↑
CS R 8.5 Moderately differentiated Ia USO No 93 DFS + P
2 39 Amenorrhea
voice raucity
Yes Testosterone↑ CS L 3 Poorly differentiated + R Ia USO NVB×6 No 112 DFS
3 60 Pelvic mass Yes Normal S L 10 Moderately differentiated Ia BSO no 102 DFS
4 28 Pelvic mass No CA125 ↑
AFP ↑
CS L 7 Poorly differentiated +R Ic CYS + USO BEP×4 No 64 DFS
5 60 Postmenopausal bleeding Yes CA199 ↑ CS L 2 Moderately differentiated
+atypical
Ia THBSO No 85 DFS
6 25 Menstrual irregularity No Testosterone ↑
AFP ↑
C L 4 Moderately differentiated + R Ia USO BEP×4 NO 66 DFS + P
7 61 Abdominal pain Yes Normal CS R 4 Moderately differentiated Ia THBSO No 36 DFS
8 48 Abdominal pain Yes Normal CS R 9 Poorly differentiated Ia THBSO+S BEP×6 No 43 DFS
9 44 Pelvic mass Yes Normal S R 7.5 Moderately differentiated Ia THBSO+S No 49 DFS
10 69 Abdominal pain Yes Normal S R 5 Moderately differentiated Ia THBSO No 20 DFS
11 58 Pelvic mass Yes Normal C R 10 Moderately differentiated Ia THBSO NO 28 DFS
12 65 Postmenopausal bleeding Yes CA125↑ CEA↑ AFP↑ CA199↑ R 0.5 Poorly differentiated +EC + R Ia THBSO+S TC×6 No 68 DFS
13 26 Amenorrhea No Normal C L 2.5 Moderately differentiated + R Ic USO BEP×4 YES 87 AWD
14 27 Menstrual irregularity No Testosterone↑
AFP
C L 4 Moderately differentiated + R Ia USO BEP×4 NO 32 DFS + P
15 28 Menstrual irregularity Yes Normal CS L 6 Moderately differentiated + R Ia USO BEP×4 No 86 DFS
  1. CS cyst and solid, C cyst, S solid, R right, L left, EC endometrial cancer, USO unilateral salpingo-oophorectomy, BSO bilateral salpingo-oophorectomy, CYS cystectomy, THBSO total hysterectomy and bilateral salpingo-oophorectomy, S(treatment) staging surgery (omentectomy ± pelvic lymphadenectomy), BEP (bleomycin + etoposide + cisplatin), NVB (nedaplatin + vincristine + bleomycin), TC (paclitaxel + carboplatin), DFS disease-free survival, DFS + P disease-free survival and pregnancy, AWD alive without disease after relapse treatment